Sign in →

Test ID DLL3 Delta-Like 3 Protein (SP347), Semi-Quantitative Immunohistochemistry, Manual, Tissue

Shipping Instructions

Attach the green pathology address label included in the kit to the outside of the transport container.

Necessary Information

A pathology/diagnostic report and a brief history are required.

Specimen Required

Specimen Type: Tissue


-Pathology Packaging Kit (T554)

-Immunostain Technical Only Envelope (T693)

Container/Tube: Immunostain Technical Only Envelope

Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, “positively charged” slides with 4-microns, formalin-fixed, paraffin-embedded tissue

Additional Information: One slide will be stained with hematoxylin and eosin and returned.

Useful For

Diagnosis of small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), amongst other tumors

Method Name

Immunohistochemistry (IHC)

Reporting Name

DLL3(SP347)Semi-Quant IHC,Manual

Specimen Type


Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)

Clinical Information

Delta-like 3 protein (DLL3) is an atypical Notch ligand induced by the neuroendocrine transcription factor, ASCL-1.  DLL3 is expressed on the cell membrane and in the cytoplasm of tumor cells. 


Positivity for this test will require 50% or more of the tumor cells within a specimen to express delta-like 3 protein with an intensity ranging from 1 to 3+.

Clinical Reference

1. Saunders LR, Bankovich AJ, Anderson WC, et al: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015 Aug;7(302):302ra136

2. Xie H, Boland JM, Maleszewski JJ, et al: Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Lung Cancer. 2019 Sep;135:73-79. doi: 10.1016/j.lungcan.2019.07.016

3. Xie H, Kaye FJ, Isse K, et al: Delta-like protein 3 expression and targeting in merkel cell carcinoma. Oncologist. 2020 Sep 1;10:810-817. doi: 10.1634/theoncologist.2019-0877

Day(s) Performed

Monday through Friday

Report Available

5 to 7 days

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
DLL3 DLL3(SP347)Semi-Quant IHC,Manual In Process


Result ID Test Result Name Result LOINC Value
603333 Interpretation 59465-5
603334 Participated in the Interpretation No LOINC Needed
603335 Report electronically signed by 19139-5
603336 Material Received 81178-6
603337 Disclaimer 62364-5
603338 Case Number 80398-1


If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.

Mayo Clinic Laboratories | IHC Catalog Additional Information: